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INTRODUCTION
Pulmonary hypertension is a condition frequently found in patients with advanced parenchymal lung diseases of different causes [1, 2] and it is defined by a resting mean pulmonary artery pressure (PAP) of 25 mmHg or higher [3] . Cystic fibrosis (CF) is an autosomal recessive disease that typically affects the lungs, eventually leading to progressive respiratory failure, pulmonary hypertension, and right ventricular dysfunction [4, 5] (Fig. 1 ). Indeed, respiratory failure continues to be the most common cause of morbidity and mortality in the disease [6 && ]. CF-associated pulmonary hypertension has been incorporated in the group III, namely 'pulmonary hypertension due to lung diseases and/or hypoxia' of the latest clinical classification of pulmonary hypertension (Dana Point, 2008) [7] . In particular, CF is part of a new subgroup called 'Other pulmonary diseases with mixed restrictive and obstructive pattern' (Table 1 ). This subgroup also includes patients with chronic bronchiectasis and a syndrome characterized by the combination of pulmonary fibrosis and emphysema.
The prevalence of pulmonary hypertension in CF patients, its impact on outcome, and potential therapeutic options have been infrequently studied; however, in the last few years, this association has gained notoriety. This article reviews the literature on pulmonary hypertension in CF and summarizes the current evidence on prognosis and treatment.
PREVALENCE OF PULMONARY HYPERTENSION IN CYSTIC FIBROSIS
Pulmonary hypertension is increasingly common in CF patients as a greater number of individuals survive to adulthood. Right heart catheterization (RHC) continues to be the gold standard for diagnosing pulmonary hypertension, given that echocardiography is inaccurate, particularly in patients with advanced lung disease [1, 2, 8] . Table 2 shows the published studies in CF patients that reported the prevalence of pulmonary hypertension by RHC [5, [9] [10] [11] [12] [13] [14] 15 && ,16 & ]. From these studies, the prevalence of pulmonary hypertension varies depending on the age of the patients (children and/or adults), severity of lung disease (variable or only severe), the methodology employed (echocardiography or RHC), and the criteria used to define patients [mean PAP !25 mmHg or mean PAP !25 mmHg with pulmonary artery occlusion pressure (PAOP) 15 mmHg]. Some studies included and other excluded patients with elevated PAOP (!15 mmHg) as this finding suggests left ventricular diastolic dysfunction. This consideration is important because left ventricular diastolic function is frequently observed in CF patients with advanced disease [17] . The exercise criteria (increase in mean PAP to >30 mmHg) was removed from the latest definition of pulmonary hypertension because of marked differences in the upper limit of normal depending on the level of activity and the age of the patients [3] . This is relevant, as adult CF patients with advanced lung disease may have significant increases in the mean PAP with exercise, a response that is probably common in these patients and may impair their functional capacity [18] .
PATHOPHYSIOLOGY
The exact mechanism by which pulmonary hypertension develops in patients with CF has not been fully elucidated. It is allegedly due to chronic alveolar hypoxia, progressive destruction of pulmonary vascular bed, and/or persistent increase in cardiac output. Nevertheless, in advanced stages of the disease, other factors may play a role such as left ventricular dysfunction (systolic and/or diastolic), portal hypertension, hypothyroidism, and/or pulmonary embolism. A summary of the mechanisms involved in the development of pulmonary hypertension in CF patients is shown in Fig. 2 .
Hypoxemia is a powerful pulmonary vasoconstrictor [9, [19] [20] [21] and occurs in CF patients as a result of lung destruction, ventilation/perfusion (V/Q) mismatch, and right-to-left shunt [22, 23] . When the pulmonary artery smooth muscle and endothelial cells sense low oxygen levels, pulmonary vasoconstriction ensues with the purpose of equilibrating ventilation and perfusion [24] . However, chronic alveolar hypoxia leads to intimal proliferation, subintimal fibrosis, and muscularization of pulmonary arterioles. This remodeling of the pulmonary arteries can increase the mean PAP, causing pulmonary hypertension and right heart failure [25] .
Chronic airway inflammation could also lead to pulmonary vascular remodeling and pulmonary
KEY POINTS
Pulmonary hypertension is frequently found in patients with cystic fibrosis and end-stage lung disease.
The degree of pulmonary hypertension is usually mild; however, there are cases of disproportional elevation of pulmonary pressures.
Pulmonary hypertension likely has a negative impact on survival.
There is no evidence that the use of specific therapies for pulmonary hypertension is of benefit in cystic fibrosis patients.
Prevention of disease progression, supportive therapy, and lung transplantation are accepted therapeutic modalities. hypertension [26, 27] . In fact, the mean PAP was significantly higher in CF patients infected with Burkholderia cepacia than in patients who were not. Interestingly, all but one isolate (that could not be subculture) belonged to the genomovar II, named Burkholderia multivorans [28] . Other mechanisms may contribute to the development of pulmonary hypertension, such as air trapping with vessel compression [29] and/or endothelial dysfunction caused by vessel inflammation or shear stress [29, 30] . Indeed, vascular endothelial dysfunction was observed in a cohort of young CF patients with fairly normal oxygen saturation and pulmonary function [31 && ]. Henno et al. [32] investigated mechanisms potentially involved in the development of pulmonary hypertension in CF patients. They assessed the vascular endothelial function in pulmonary arterial rings isolated from lungs of CF patients who underwent transplantation. A subset of CF patients (61%) had pulmonary vascular endothelial dysfunction and of those a high proportion had pulmonary hypertension (71%). Conversely, in patients with normal endothelial function, none had pulmonary hypertension. In addition, the authors noted that in patients with endothelial dysfunction, endothelin-1 (a strong vasoconstrictor involved in vascular remodeling) was higher and the blockage of its receptor produced a marked vasodilator effect. Similarly, in another study of CF patients, plasma endothelin levels were noted to be directly associated with disease severity [33] .
Recent investigations have studied the function of the right ventricle (RV) in CF patients. Using modern echocardiographic techniques, two prospective studies demonstrated the presence of RV dysfunction in these patients who had no or mild pulmonary disease [34 & ,35 & ]. The reasons for the abnormalities in the structure and function of the RV at early stages of the CF disease are not clear, since traditionally the RV dysfunction was thought to be secondary to raised PAP in the setting of chronic hypoxia [36] . Potential factors that may affect the RV in CF include chronic inflammation, direct involvement of the heart by the disease, and increased levels of neurohormones [34 & ,35 & ]. Interestingly, a few studies demonstrated that the CF transmembrane conductance regulator (CFTR) intervenes in the regulation of the cardiomyocyte contraction by maintaining a resting membrane potential and preventing an overload of intracellular calcium that can lead to hypercontraction [37] . In addition, the activation of myocardial CFTR protects against necrotic myocardial injury induced by ischemia/reperfusion [38] . Thus, the reduced myocardial activity of CFTR in CF patients may help explain the RV dysfunction in early stages of disease and the development of disproportionate elevation of PAP in some individuals. More importantly, further investigations on the role of cardiac CFTR may lead to novel therapies that target this pathway.
There is growing evidence supporting an association between CF and hypothyroidism [39, 40] or pulmonary embolism, two conditions that can participate in the pathogenesis of pulmonary hypertension. CF-related thyroid disorders have been reported by some authors [39, 40] , possibly due to iodine deficiency [40] or mutations of the CFTR protein that affects the transport of ions across the epithelia and secretion of thyroid hormone [41] . A link between hypothyroidism and pulmonary arterial hypertension (PAH) was initially suggested 30 years ago [42] and subsequently supported by other studies [43] [44] [45] . The mechanistic origin of this association is not clear, but an underlying autoimmune process may contribute to both disorders. The risk of venous thromboembolism is increased in CF patients due to the presence of a central venous catheter, immobility, and acquired thrombophilia secondary to inflammation, vitamin K deficiency, and/or liver dysfunction [46] . Studies in non-CF patients presenting with acute pulmonary embolism showed that a small percentage (0.6-4%) of patients developed chronic thromboembolic pulmonary hypertension due to persistent fibrotic obstruction and vascular remodeling of the pulmonary arteries [47] . that the mean PAP was not able to predict mortality. The mean PAP was 26 AE 5 mmHg in patients who were alive at the end of the study versus 28 AE 7 mmHg in those who died awaiting lung transplantation (P ¼ 0.15). However, a higher systolic PAP (in 5-mmHg increments) was an independent risk factor for death after adjusting for confounders [hazard ratio: 1.41 (95% confidence interval 1.11-1.8)]. Similarly, in CF patients evaluated for lung transplantation, Tonelli et al. [5] found no difference in survival at 5 years in patients with (40.8%) or without pulmonary hypertension (55.7%, P ¼ 0.51); however, the authors noted that patients with mean PAP of at least 40 mmHg had a trend toward worse survival than those with a mean PAP below that cut-off (1-year survival 50% versus 83%, P ¼ 0.08).
IMPACT ON OUTCOME
In ] further investigated the impact of pulmonary hypertension on the survival of CF patients evaluated for lung transplant. The authors found that the presence of pulmonary hypertension in an unadjusted analysis did not affect their survival either before or after lung transplantation; however, patients with pulmonary hypertension had findings suggestive of more advanced CF disease as evidenced by the oxygen needs, spirometry, and functional capacity.
It is possible that pulmonary hypertension is a consequence of the advanced lung disease that develops in CF. As in chronic obstructive pulmonary disease (COPD), the degree of pulmonary hypertension in CF patients is usually mild; yet there is a group of patients who have higher pulmonary pressures for the degree of lung disease. In CF, a mean PAP of at least 35 or 40 mmHg could be considered a disproportionate elevation of PAP that may be associated with worse outcomes, as noted in patients with COPD [49, 50] .
Echocardiography has limited accuracy in the diagnosis of pulmonary hypertension, especially in the presence of parenchymal lung diseases [1] . However, a number of studies in CF patients have investigated the prognostic value of several echocardiographic parameters. Fraser et al. [36] found that an elevated right ventricular systolic pressure (>35 mmHg) was associated with increased mortality in CF patients with severe lung disease (FEV 1 less than 40%). More recently, Bright-Thomas et al. [51 & ] found that adult CF patients, with different degrees of pulmonary involvement, had higher estimated right ventricular systolic pressures than age-matched and sex-matched healthy controls. The estimated right ventricular systolic pressure directly correlated with disease severity; however, it did not predict survival when adjusted for FEV 1 and arterial partial pressure of oxygen. Manika et al. [52 & ] studied whether right ventricular systolic pressure has an impact on exercise capacity in adult CF patients with mild-to-moderate lung disease (FEV 1 !40% of predicted). Within 1 min postexercise, patients with CF (n ¼ 17) had higher estimated right ventricular systolic pressure than age-matched and height-matched healthy controls (n ¼ 10), and this echocardiographic measurement was associated with impaired exercise capacity.
Pulmonary flow acceleration time is the interval between the onset of ejection and the peak velocity of the pulmonary flow. This time is indirectly associated with mean PAP. Its main advantage is that it is measurable in most patients, unlike the right ventricular systolic pressure. Damy et al. [53 & ] prospectively studied the pulmonary flow acceleration time in patients with CF (FEV 1 <60%) and found that individuals in the lowest tertile had more advanced lung disease with a shorter time to lung transplantation than those in the other tertiles.
In pulmonary hypertension, pulmonary arterial pressures are not good predictors of outcome because the pressures may decline when the RV fails and is no longer able to maintain an appropriate cardiac output. For this reason, the RV function may be a better predictor of outcomes. In fact, once CF patients develop right heart failure, the prognosis is usually poor. Stern et al. [11] reported a median survival of 4 months after onset of cardiac dilation and fluid retention in CF patients. Belkin et al. [54] found that the presence of RV dysfunction was more common in CF patients who died (51%) compared with those awaiting lung transplantation (21%). However, the presence of pulmonary hypertension was not different between survivors (21%) and nonsurvivors (29%).
There is increasing recognition of the role of circulating biomarkers in pulmonary hypertension. The brain natriuretic peptides (BNPs) are secreted by the cardiac myocytes and in pulmonary hypertension reflect the stress imposed on the RV [55] . Both BNP and N-terminal-pro-BNP (NT-pro-BNP) have been associated with higher mortality in PAH [56] [57] [58] . CF patients without heart failure had similar levels of NT-pro-BNP to those of the general population and more importantly this peptide was not associated with FEV 1 or pulse oxygen saturation [59] . Consequently, a high level of NT-pro-BNP may suggest the presence of pulmonary hypertension or heart failure [59] ; however, further investigations are needed to confirm this hypothesis.
TREATMENT OPTIONS FOR PULMONARY HYPERTENSION IN CYSTIC FIBROSIS PATIENTS
Although there are data supporting that pulmonary hypertension is associated with worse outcomes in CF, no information is available to determine whether the treatment with pulmonary hypertension-specific therapies is of benefit. As pulmonary hypertension may be a reflection of disease severity, its treatment might not necessarily improve outcomes. At this point, prevention of lung disease or its progression is the most important intervention. Therefore, adequate treatment of patients with CF is needed to delay the progression of the respiratory disease and consequently the development of pulmonary hypertension [20] .
In a small group of CF patients, oxygen supplementation was demonstrated to decrease mean PAP and pulmonary vascular resistance [60, 61] , as well as improve RV performance [62] . Goldring et al. [9] performed RHC in CF patients (n ¼ 21) breathing different oxygen mixtures (fraction of inspired oxygen: 15-100%) and found that hypoxic mixtures increased and high-oxygen mixtures reduced the mean PAP. However, no studies have assessed the hemodynamic effects of continuous long-term oxygen administration to CF patients with pulmonary hypertension. Nocturnal supplemental oxygen over 3 years showed no effect on mortality, hospitalizations, or progression of disease in a small study of CF patients [63] . The CF adult care consensus report expressed that one of the goals of oxygen therapy is the prevention of the development and/or progression of pulmonary hypertension and recommends the screening of CF patients with moderate-to-severe respiratory disease for the presence of hypoxemia during exercise or sleep [64] .
Diuretics have a place in the treatment of pulmonary hypertension in the setting of hypervolemia and elevated PAOP. In advanced cases, care should be exercised to avoid a rapid reduction in the intravascular volume that may decrease the filling of the RV and hence impair cardiac output [20] . Digoxin does not seem to be beneficial in improving symptoms or survival in CF patients with right heart failure [11] . Anticoagulation is indicated in some patients with group I pulmonary hypertension (PAH) [65] but not in pulmonary hypertension due to CF because of the lack of evidence to support its use and the possibility of increasing the risk of bleeding [66] . A small number of CF patients with pulmonary hypertension have been treated with vasodilator agents such as nifedipine, diltiazem, and hydralazine; nevertheless, no benefits were derived from these therapies, possibly because these agents increased the flow to nonventilated portions of the lung, accentuating right-to-left shunts and worsening hypoxemia [60, 61, 67] .
Pulmonary hypertension-specific therapies have not been well studied in CF patients with pulmonary hypertension. Phosphodiestearase-5 inhibitors like sildenafil may be useful in these patients; however, this treatment continues to be controversial in pulmonary hypertension due to parenchymal lung diseases such as COPD and interstitial lung disease [68] [69] [70] [71] . Montgomery et al. [72] showed that sildenafil improved exercise tolerance and reduced PAP in a patient with severe CF lung disease and pulmonary hypertension. Interestingly, phosphodiestearase-5 inhibitors are particularly attractive in CF patients with the most common disease allele (F508del), as they may promote the activity of the chloride channel (CFTR), the essential transepithelial ion transport abnormality in this condition [73 && ]. Inhaled prostacyclin analogues may theoretically increase the pulmonary artery vascular flow in well ventilated areas of the lung, potentially improving the match between ventilation and perfusion. Up to the time of this writing, there is only one case report showing that aerosolized iloprost lowered the PAP, improved the functional status, and facilitated lung transplantation in a patient with CF and pulmonary hypertension [74] . Promising results have also been observed with the use of inhaled prostacyclin analogues in patients with pulmonary hypertension due to other lung diseases [75] [76] [77] . Parenteral prostacyclin analogues are usually not given to patients with pulmonary hypertension due to lung diseases as they may worsen the ventilation/perfusion match and oxygenation. Endothelin receptor antagonists such as bosentan and ambrisentan have not been tested in pulmonary hypertension related to CF. Furthermore, in patients with COPD, the utility of these medications is controversial [78] and in certain patients may worsen the functional status and oxygenation [79] .
Lung transplantation is a valid treatment alternative for patients with a predicted survival shorter than what would be expected after transplantation; thus, this intervention is indicated when the 2-year to 3-year predicted survival from the lung disease is less than 50% [80, 81] . Although lung transplantation showed no significant effect on the survival of CF children who were on the waiting list from 1992 through 2002 [82] , a recent study after the implementation of the lung allocation score (May 2005) showed that lung transplantation conferred a survival benefit in adult CF patients, directly related to the severity of disease [6 && ]. In part this is due to better surgical techniques, organ preservation, critical care, and posttransplant management [83] . At this point, lung transplantation remains the only option that improves the survival and quality of life of CF patients with end-stage lung disease [81] . In fact, after lung transplantation, the median survival of CF patients is 7.5 years, better than other diagnoses like COPD or idiopathic pulmonary fibrosis [84 && ]. The selection of the appropriate candidate for lung transplant is based on a comprehensive evaluation that incorporates several indicators of disease severity, including pulmonary hypertension [80, 85] . In fact, the International Guidelines for the Selection of Lung Transplant Candidates includes pulmonary hypertension as one of the factors to consider when deciding to perform lung transplantation in CF patients [80] . The new allocation system of the United Network for Organ Sharing (UNOS) considers several determinants of disease severity in CF, including systolic PAP [86] . Importantly, lung transplantation is not contraindicated in patients with pulmonary hypertension and RV dysfunction as the RV function rapidly recovers after the intervention [81, 87] .
AREAS FOR FURTHER RESEARCH
Areas of special interest in CF that need further investigation are as follows:
(1) Study of the mechanisms for the development of pulmonary hypertension in CF patients, with special emphasis on comprehending why some CF individuals have disproportionate pulmonary hypertension in relation to the degree of lung disease. (2) Recognition of the prevalence, impact, and prognostic implications of exercise-induced pulmonary hypertension in CF. (3) Investigation of the origin of RV dysfunction in patients with mild CF. (4) Examination of the value of using pulmonary hypertension-specific therapies to treat pulmonary hypertension in CF patients.
CONCLUSION
Pulmonary hypertension is common in patients with CF and advanced lung disease. Pulmonary hypertension may be associated with worse outcome and its identification may provide an opportunity for treatment, although no clinical trials using pulmonary hypertension-specific therapies have been carried out to date.
